ReviewPharmacoEconomics1997
The effect of pharmacoeconomics on company research and development decisions.
Review in PharmacoEconomics, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Introduction of early health technology assessment for innovators, clinicians, and funders.npj health systems · 2026Review
- Research on Co-Opetition Mechanism between Pharmaceutical Enterprises and Third-Party Logistics in Drug Distribution of Medical Community.International journal of environmental research and public health · 2022Article
- A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development.Medical journal of the Islamic Republic of Iran · 2021Article
- Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development.PharmacoEconomics · 2020Article
- The premarket assessment of the cost-effectiveness of a predictive technology "Straticyte™" for the early detection of oral cancer: a decision analytic model.Health economics review · 2017Article
- Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.PharmacoEconomics · 2017Article
- Early decision-analytic modeling - a case study on vascular closure devices.BMC health services research · 2015Article
- Role of pharmacoeconomic analysis in R&D decision making: when, where, how?PharmacoEconomics · 2005Review
- An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.PharmacoEconomics · 2003Article
- Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?PharmacoEconomics · 2001Review
- Emerging role of pharmacoeconomics in the research and development decision-making process.PharmacoEconomics · 2001Article
- The distribution of sales revenues from pharmaceutical innovation.PharmacoEconomics · 2000Article
- The dilemma of new drugs. Are costs rising faster than effectiveness?PharmacoEconomics · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a strong rationale for integrating pharmacoeconomics into research and development (R&D) project selection and termination decisions. The average cost for the typical new drug introduction now exceeds $US300 million. Furthermore, a growing proportion of phase III projects are terminated because of economic factors relative to efficacy and safety concerns. While the use of pharmacoeconomic studies by payers is still evolving, the pressures on firms to show that new products are cost effective will only intensify in future periods. Accordingly, it is important for firms to begin analysing the cost effectiveness of new drug candidates early in the R&D process. The cost effectiveness of a new therapy can be simulated prior to clinical testing using different assumptions about the efficacy, tolerability, pricing and formulation of the new therapy. These models can be refined and updated as data become available from clinical testing and other sources. A key objective is to make uncompetitive projects fail sooner while channelling development resources to projects with high expected returns. Cost-effectiveness analysis should be an integral component of the firms's strategic action plan and its return on investment analyses.
Indexed as
Identifiers
10168028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.